23andMe warns of ‘substantial doubt’ over its survival without new funding
Once-hyped genetic start-up issues latest guidance after reporting further quarterly revenue declines
Read more at Financial Times
-
23andMe’s stock falls after company says there’s substantial doubt it can stay in business
Business - MarketWatch - November 12 -
Boeing supplier Spirit AeroSystems says there’s ‘substantial doubt’ about its ability to keep operating
Business - MarketWatch - November 6 -
DNA-testing site 23andMe fights for survival
Top stories - BBC News - November 3 -
Doubts mount over Britain’s ambitious growth plans — with warnings of further tax rises possible
Business - CNBC - 4 days ago -
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
Business - MarketWatch - November 12 -
DNA-testing site 23andMe to lay off 40% of its workers
Top stories - BBC News - November 12 -
23andMe cuts 40% of its workforce and discontinues therapeutics division
Health - ABC News - November 12 -
23andMe to lay off 40% of its workforce as stock price plummets
Top stories - CBS News - November 12 -
Ukraine conducts first Russia attack with U.S. missiles; Putin lowers bar for nuclear strike
Top stories - NBC News - 4 days ago
More from Financial Times
-
Goldman Sachs takes $900mn hit on Northvolt investment
Business - Financial Times - 8 hours ago -
‘There was so much promise’: How Northvolt tumbled into bankruptcy
Business - Financial Times - Yesterday -
Inside the bitter fight to become Donald Trump’s Treasury secretary
Business - Financial Times - 8 hours ago -
The age of the partial outsider
Business - Financial Times - 19 hours ago -
Meta loses ground to Bluesky as users abandon Elon Musk’s X
Business - Financial Times - 11 hours ago